Antibody responses to trivalent influenza vaccine in Iranian adults infected with human immunodeficiency virus.
AbstractThe serious influenza-associated complications among immunodeficient individuals such as those who are infected with human immunodeficiency virus (HIV), highlights the importance of influenza vaccination in these people. Therefore, the current study aimed to investigate the antibody responses to influenza vaccine in this group. Two hundred subjects were recruited, during autumn 2010 and 2011, to receive, trivalent inactivated influenza vaccine consisting of A (H1N1), A (H3N2), and B strains. Hemagglutination inhibition assay was used to measure the antibody titer against all strains of the vaccine prior and one month post vaccination. Seroconversion rate for A (H1N1), A (H3N2), and B were found to be 58.5%, 67% and 64.5%, respectively. No correlation was found between antibody titer and demographics factors such as age and gender; however, we found a significant correlation between antibody titer and CD4 cell count. Checking the local and systemic reactions after vaccination, the pain on the injection site and myalgia were the most common local and systemic reactions with 20% and 6.5%, respectively. As vaccination with influenza mount considerable antibody responses in HIV-infected patients, annual influenza vaccination seems to be rational in order to prevent or reduce the severe clinical complications induced by influenza virus.
John, Treano R. Influenza viruses, Avian influenza and swine influenza in: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious disease. 7th ed Philadelphia; churchil living stone; 2010.P. 2265-84.
Kunisaki KM, Janoff EN. Influenza in immunosuppressed Populations: a Review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis. 2009;9(8): 493-504.
Cavdar C, Sayan M, Sifil A, Artuk C, Yilmaz N, Bahar H, Camsari T. The comparison of antibody response to influenza vaccination in continuous ambulatory peritonealmdialysis, hemodialysis and renal transplantation patients.Scand j urol Nephrol 2003; 37(1):71-6.
Radwan HM, Cheesman SH, Lai KK, Ellison III RT Influenza in Human immunodeficiency virus- infected patients during the 1997-1998 influenza seasons. Clin Infect Dis 2000;31(2):604-6.
Zanetti AR, Amendola A, Besana S, Boschini A, Tanzi E. Safety and immunogenicity of influenza vaccination in individuals infected with HIV. Vaccine 2002: 20 Supple 5: B29-32.
Cagig A, Nilson A, Pensieroso S, Chiodi F. Dysfuntional B- Cell responses during HIV 1 infection: Implication for influenza vaccination and highly active antiretroviral therapy. Lancet infect Dis. 2010; 10(7):499-503.
Malaspina A, Moir S, Orsega SM, Vasquez J, Miller NJ, Donoghue ET, Kottilil S, Gezmu M, Follmann D, Vodeiko GM, Levandowski RA, Mican JM, Fauci AS. compromised B Cell Responses To Influenza Vaccination in HIV- Infected Individuals. J Infect Dis 2005;191(9):1442-50.
Nelson KE, Clements ML, Miotti P, cohn S, polk BF. The influence of human immunodeficiency virus (HIV) infection on antibody responses to influenza vaccines. Ann Intern Med.1988; 109(5): 383-8.
Viganò A, Zuccotti GV, Pacei M, Erba P, Castelletti E, Giacomet V, Amendola A, Pariani E, Tanzi E, Clerici M. Humoral and cellular response to influenza vaccine in HIV-infected children with full viroimmunologic response to Antiretroviral therapy. J Acquir Immune Defic syndr. 2008; 48(3): 282-96.
Kroon FP, Van Dissel JT, de Jong JC, Zwinderman K, Furth R. Antibody response after influenza vaccination in HIV- infected individuals: a consecutive 3-year study. Vaccine 2000;18(26): 3040-9.
EMEA. Note for Guidance on hormonisation of Requirements for influenza vaccine. Committee for proprietary medicinal products (CPMP) EMEA- 12 Mars 1997- CPMP/ BWP/ 214/96.
Bridges CB, Harper SA, Fukuda K, Uyeki TM, Cox NJ, Singleton JA. Advisory Committee on Immunization Practices.Prevention and control of influenza: recommendation of the Advisory committee onImmunization practice (ACIP). MMWR Recomm Rep 2010; 59:1-62.
Tebas P, Frank I, Lewis M, Quinn J, Zifchak L, Thomas A, Kenney T, Kappes R, Wagner W, Maffei K, Sullivan K. Center for AIDS Research and Clinical Trials Unit of the University of Pennsylvania. Poor immunogenicity of the H1N1 2009 vaccine in well controlled HIV- infected individuals. AIDS 2010;24(14):2187-92.
Fulller JD, Craven DE, Steger KA, Cox N, Heeren TC, Chernoff D. Influenza vaccination of human immunodeficiency virus (HIV) infected adults: impact on plasma levels of HIV type 1 RNA and deter minants of antibody responses. Clin Infect Dis. 1999; 28(3): 541-7.
Evison J, Farese S, Seitz M, Uehlinger DE, Furrer H, Muhlemann K. Randomized, Double- Blind Comparative Trial of subunit and virosomal influenza vaccines for immunocompromised patients. Clin Infec Dis 2009;48(10):1402-12.
Madhi SA, Maskew M, Koen A, Kuwanda L, Besselaar TG, Naidoo D, Cohen C, Valette M, Cutland CL, Sanne I.Trivalent inactivated influenza vaccine in African Adults infected with Human Immunodeficient virus: Double Blind, Randomized clinical Trial of Efficacy, immunogenicity, and safety. Clin Infect Dis 2011;52(1):128-37.
Sullivan PS, Hanson DL, Dworkin MS, Jones JL, Ward JW. Adult and Adolescent Spectrum of HIV Disease Investigators. Effect of influenza vaccination on disease progression among HIV infected persons. AIDS 2000; 14(17): 2781-5.
Tasker SA, Treanor JJ, Paxton WB ,Wallac MR. Efficacy of influenza Vaccination in HIV infected persons. A Randomized, double blind, placebo- controlled Trial. Ann Intern Med 1999; 131(6): 430-3.
Hajiabdolbaghi M, Jam S, SeyedAlinaghi SA, Jafari S, MoradmandBadie B, Sabzvari D. Advers Reactions of Trivalent Influenza vaccine in HIV – infected Individuals. Acta Medica Iranica. 2010; 48(2): 95-100.
Hajiabdolbaghi M, Jafari S, Esteghamati AR, Dadras MN, Gouya MM, Jam S, EmadiKoochak H, Kheirandish P, Shahriari S, MoradmandBadie B. Advers Events of Trivalent influenza vaccine among Health care worker in Iran. Iranian J Publ Health 2009;38(2): 51-7.